LENZ

LENZ Therapeutics

23.25 USD
+0.28
1.22%
Updated Mar 12, 11:01 AM EDT
1 day
1.22%
5 days
3.29%
1 month
-6.40%
3 months
-24.46%
6 months
12.59%
Year to date
-17.82%
1 year
43.52%
5 years
43.52%
10 years
43.52%
 

About: LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

0
Funds holding %
of 7,363 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

167% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 9

48% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 21

29% more capital invested

Capital invested by funds: $445M [Q3] → $573M (+$128M) [Q4]

19% more funds holding

Funds holding: 78 [Q3] → 93 (+15) [Q4]

4.08% more ownership

Funds ownership: 68.15% [Q3] → 72.23% (+4.08%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for LENZ.

Financial journalist opinion

Based on 3 articles about LENZ published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, March 19, 2025, at 4:30 p.m. EST to report its fourth quarter and full year 2024 financial results and recent corporate highlights.
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
Neutral
GlobeNewsWire
1 week ago
LENZ Therapeutics to Host Commercial Day on April 15, 2025
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that it will host a Commercial Day to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia. The event will take place on Tuesday, April 15, 2025, from 2:00 p.m.
LENZ Therapeutics to Host Commercial Day on April 15, 2025
Neutral
GlobeNewsWire
2 weeks ago
LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
LENZ Therapeutics to Participate in Upcoming Investor Conferences
Positive
Zacks Investment Research
3 months ago
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for LENZ Therapeutics, Inc. (LENZ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now
Neutral
GlobeNewsWire
3 months ago
LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
LENZ Therapeutics to Participate in Upcoming Investor Conferences
Positive
Zacks Investment Research
3 months ago
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know
Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know
Neutral
Seeking Alpha
4 months ago
LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President and CEO Shawn Olsson - CCO Marc Odrich - CMO Conference Call Participants Yigal Nochomovitz - Citi Marc Goodman - Leerink Partners Joe Catanzaro - Piper Sandler Pavan Patel - Bank of America Lachlan Hanbury-Brown - William Blair Gary Nachman - Raymond James Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics' Third Quarter 2024 Conference Call.
LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript
Positive
Benzinga
4 months ago
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
On Sunday, Corxel Pharmaceuticals and LENZ Therapeutics LENZ released topline data from the Phase 3 JX07001 trial of LNZ100 in patients with presbyopia in China.
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
Neutral
GlobeNewsWire
4 months ago
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment,and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically significant in the LNZ100 treatment group compared to the vehicle group (p
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
Neutral
GlobeNewsWire
4 months ago
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
Charts implemented using Lightweight Charts™